金吾财讯 | 丹麦生物技术初创公司Orbis Medicine宣布，已与抗糖尿病及减肥药巨头诺和诺德（NVO）达成一项总价值最高可达14亿美元的药物研发合作协议，旨在共同开发针对心血管及代谢类疾病的新一代疗法。根据协议，本次合作将利用Orbis旗下由人工智能驱动的nGen平台，加速用于心血管与代谢靶点的口服大环化合物药物研发。作为合作的一环，诺和诺德将对Orbis进行战略投资。Orbis有权获得来自诺和诺德最高达14亿美元的资金支持，其中包括预付款、后续潜在的研发与商业化里程碑付款等。Orbis首席执行官Morten Graugaard表示，与诺和诺德的强强联合将充分释放AI赋能大环药物研发的变革潜力，推动心血管与代谢疾病口服治疗方案的创新。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.